Abstract
Introduction: The aim of this study is to evaluate the quality of photodynamic diagnosis (PDD) and transurethral resection of bladder tumors (TURBT) among different urologists. Patients and Methods: The selected data consists of 194 patients, 268 5-aminolevulinic acid (5-ALA)-induced PDD procedures and 934 biopsies. Tumors were resected and biopsies were taken from suspicious areas under guidance of white light endoscopy and 5-ALA-induced fluorescence cystoscopy. The quality of PDD was determined by evaluating the mean number of tumors resected by 5 urologists and, thereafter, assessing the time to recurrence between groups. Results: Urologist 1 took 37% more biopsies (p < 0.001) and diagnosed 42% more tumors (p = 0.005) and 46% more false positives (p < 0.001) from bladders compared to urologists 2, 3, 4 and 5 together. The mean time to bladder cancer recurrence for all recurrences within 0–18 months was 11.0 months for operator 1 and 8.3 months for the other urologists (p = 0.01). Conclusions: The resecting urologist appears to be an important factor for the quality of standard and PDD-assisted TURBT. Learning curve programs may be required with experienced surgeons accompanying those with less experience.
Journal Section:
Editor's choice
References
1.
Jichlinski P, Leisinger HJ: Fluorescence cystoscopy in the management of bladder cancer: a help for the urologist! Urol Int 2005;74:97–101.
2.
Jocham D, Stepp H, Waidelich R: Photodynamic diagnosis in urology: state-of-the-art. Eur Urol 2008;53:1138–1150.
3.
Burger M, Stief CG, Zaak D, Stenzl A, Wieland WF, Jocham D, Otto W, Denzinger S: Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors. Urology 2009;74:1282–1286.
4.
Witjes JA, Redorta JP, Jacqmin D, Sofras F, Malmstrom PU, Riedl C, Jocham D, Conti G, Montorsi F, Arentsen HC, Zaak D, Mostafid AH, Babjuk M: Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. Eur Urol 2010;57:607–614.
5.
Hungerhuber E, Stepp H, Kriegmair M, Stief C, Hofstetter A, Hartmann A, Knuechel R, Karl A, Tritschler S, Zaak D: Seven years’ experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 2007;69:260–264.
[PubMed]
6.
Filbeck T, Roessler W, Knuechel R, Straub M, Kiel HJ, Wieland WF: 5-aminolevulinic acid-induced fluorescence endoscopy applied at secondary transurethral resection after conventional resection of primary superficial bladder tumors. Urology 1999;53:77–81.
[PubMed]
7.
Draga RO, Grimbergen MC, Kok ET, Jonges TN, Bosch JL: Predictors of false positives in 5-aminolevulinic acid-induced photodynamic diagnosis of bladder carcinoma: identification of patient groups that may benefit most from highly specific optical diagnostics. Urology 2009;74:851–856.
8.
Jichlinski P, Forrer M, Mizeret J, Glanzmann T, Braichotte D, Wagnieres G, Zimmer G, Guillou L, Schmidlin F, Graber P, van den BH, Leisinger HJ: Clinical evaluation of a method for detecting superficial surgical transitional cell carcinoma of the bladder by light-induced fluorescence of protoporphyrin IX following the topical application of 5-aminolevulinic acid: preliminary results. Lasers Surg Med 1997;20:402–408.
[PubMed]
9.
Epstein JI, Amin MB, Reuter VR, Mostofi FK: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder – Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435–1448.
[PubMed]
10.
Bates D: The lme4 Package. http://cran.r-project.org/web/packages/lme4/lme4.pdf.
11.
Cleveland W: Robust locally weighted regression and smoothing scatterplots. J Amer Stat ASSOC 1979;74:829–839.
12.
Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2,596 patients from seven EORTC trials. Eur Urol 2006;49:466–465.
[PubMed]
13.
Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C, Nseyo U, Droller MJ: A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007;178:62–67.
[PubMed]
14.
Jocham D, Witjes F, Wagner S, Zeylemaker B, van Moorselaar J, Grimm MO, Muschter R, Popken G, Konig F, Knuchel R, Kurth KH: Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005;174:862–866.
15.
Schumacher MC, Holmang S, Davidsson T, Friedrich B, Pedersen J, Wiklund NP: Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. Eur Urol 2010;57:293–299.
16.
Soloway MS, Sofer M, Vaidya A: Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 2002;167:1573–1583.
[PubMed]
17.
Divrik T, Yildirim U, Eroglu AS, Zorlu F, Ozen H: Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer? J Urol 2006;175:1258–1261.
[PubMed]
18.
Jakse G, Algaba F, Malmstrom PU, Oosterlinck W: A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol 2004;45:539–546.
[PubMed]
19.
Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, Vogeli TA: Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003;170:433–437.
[PubMed]
20.
Brausi M, Sylvester R, Van der Meijden A, Kurth KH, Members of the EORTC SBS and QC Groups: Does the surgeon have an impact in the outcome of patients with Ta-T1 TCC of the bladder? Results of an EORTC quality control study on TURBT. Eur Urol 2001;39(suppl 5):119.
21.
Babjuk W, Oosterlinck W, Sylvester R, Kaasinen E, Boehle A, Palou J: EAU Guidelines on TaT1 (Non-Muscle Invasive) Bladder Cancer. European Association of Urology, 2009.
22.
Walker L, Liston TG, LLoyd-Davies RW: Does flexible cystoscopy miss more tumours than rod-lens examination? Br J Urol 1993;72:449–450.
[PubMed]
23.
Inoue K, Karashima T, Kamada M, Shuin T, Kurabayashi A, Furihata M, Fujita H, Utsumi K, Sasaki J: Regulation of 5-aminolevulinic acid-mediated protoporphyrin IX accumulation in human urothelial carcinomas. Pathobiology 2009;76:303–314.
[PubMed]
24.
Steinbach P, Weingandt H, Baumgartner R, Kriegmair M, Hofstadter F, Knuchel R: Cellular fluorescence of the endogenous photosensitizer protoporphyrin IX following exposure to 5-aminolevulinic acid. Photochem Photobiol 1995;62:887–895.
[PubMed]
25.
Krieg RC, Messmann H, Rauch J, Seeger S, Knuechel R: Metabolic characterization of tumor cell-specific protoporphyrin IX accumulation after exposure to 5-aminolevulinic acid in human colonic cells. Photochem Photobiol 2002;76:518–525.
[PubMed]
26.
Brausi M, Gavioli M, Peracchia G, Viola M, Giliberto G, Simonini G, de Luca G, Borelli A, Bertoni V, Verrini G: Dedicated teaching programs (DTP) can improve the quality of TUR of non-invasive bladder tumors (NMIBT): experience of a single institution. Eur Urol 2008;179(suppl 4):615–616.
© 2012 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2012
You do not currently have access to this content.
